Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of SHR-1316(sc) injection, a humanized anti-PD-L1 monoclonal antibody subcutaneous formulation intended for first-line treatment of extensive-stage small cell lung cancer [1] Company Summary - The drug SHR-1316(sc) is developed independently by the company and represents a significant advancement in its oncology portfolio [1] - The total research and development investment for the related project has reached approximately 815 million yuan [1]

Core Viewpoint - A-share companies are increasingly interested in the "A+H" listing model, with several firms announcing plans to list in Hong Kong, driven by the establishment of a fast-track process for high-market-cap A-share companies by the Hong Kong Stock Exchange and the ongoing internationalization strategies of A-share enterprises [1] Group 1 - Heng Rui Medicine (600276) and Ningde Times (300750) have officially passed the listing hearing of the Hong Kong Stock Exchange [1] - Other A-share companies such as Silis (601127), Zhaowei Electromechanical (003021), and Dongpeng Beverage (605499) have also announced plans to list in Hong Kong [1] - The "A+H" listing model is gaining popularity, providing strong momentum for the development of the Hong Kong IPO market [1]

Group 1 - Roche Pharmaceuticals announced an investment of 2.04 billion RMB to establish a biopharmaceutical production base in Shanghai, aimed at enhancing its supply chain and local production in China, with completion expected in 2029 and production starting in 2031 [1] - Hengrui Medicine's application for the market approval of its CDK4/6 inhibitor, Hydroxyethyl Sulfonate Darsilil Tablets, has been accepted by the National Medical Products Administration, targeting hormone receptor-positive, HER2-negative early or locally advanced breast cancer [2] - Sanyou Medical plans to establish a joint venture with South Korea's CGBio to research innovative cell biological materials in regenerative medicine, marking a significant step in this field [3] Group 2 - ST Kelly has elected a new chairman, Wang Chong, following the recent resignation of both the chairman and the general manager, with the board voting in favor of the appointment [4] - Yunding New Medicine's core product, Naimu Kang, has received full approval from the National Medical Products Administration for treating primary immunoglobulin A nephropathy in adults, becoming the first and only drug in China approved for this indication [5]

Group 1 - Several A-share companies, including Heng Rui Medicine and Ningde Times, have recently announced their successful completion of the Hong Kong Stock Exchange listing hearing, indicating a growing interest in the "A+H" listing model among A-share companies [1][2] - The "A+H" listing model is gaining popularity due to the establishment of a fast track for high market capitalization A-share companies by the Hong Kong Stock Exchange and the Hong Kong Securities and Futures Commission, which injects strong momentum into the development of the Hong Kong IPO market [1][6] - As of May 8, over 150 companies are in the queue for listing on the Hong Kong Stock Exchange, including more than 20 A-share companies such as Heng Rui Medicine and Ningde Times [2] Group 2 - The internationalization strategy is a key driver for many A-share companies choosing to list in Hong Kong, with Heng Rui Medicine aiming to enhance its global brand influence and optimize its capital structure through this listing [3][4] - Companies like Zhongwei Co. and Hehui Optoelectronics are also pursuing Hong Kong listings to accelerate their international strategies and enhance their overseas financing capabilities [4][5] - The first quarter of 2025 saw a strong performance in the Hong Kong IPO market, with 15 IPOs completed, raising approximately HKD 18.6 billion, positioning it as the fifth largest exchange globally [6][7] Group 3 - The "A+H" listing model is particularly appealing, with 12 new applications in the first quarter of 2025 compared to only 2 in the fourth quarter of 2024, indicating a significant increase in interest [7] - The industrial market accounts for about 50% of the companies currently processing "A+H" listing applications, while healthcare and consumer goods sectors represent 22% and 14% respectively [7] - Deloitte predicts around 80 new stocks will be listed in the Hong Kong market in 2025, with expected financing between HKD 130 billion to 150 billion, primarily from large A-share companies and leading domestic enterprises [7]

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside of 15% to 35% [6][11]. Core Insights - The company reported a Q1 2025 revenue of 7.21 billion RMB, representing a year-over-year increase of 20.1%, and a net profit of 1.87 billion RMB, up 36.9% year-over-year, which aligns with expectations [6]. - The significant profit growth in Q1 is attributed to a $75 million upfront payment from IDEAYA for a licensing agreement related to a targeted ADC product, with an estimated core revenue growth of approximately 11% after excluding this payment [8]. - The company has a robust pipeline with 26 innovative molecules entering clinical stages in 2024, covering various therapeutic areas, and is expected to showcase 15 innovative drugs at the upcoming ASCO conference [8]. - Future profit projections estimate net profits of 6.98 billion RMB, 8.75 billion RMB, and 10.4 billion RMB for 2025, 2026, and 2027, respectively, with year-over-year growth rates of 10.2%, 25.3%, and 18.9% [10]. Summary by Sections Company Overview - The company operates in the pharmaceutical and biotechnology sector, with a market capitalization of 328.9 billion RMB and a share price of 51.56 RMB as of May 7, 2025 [1]. Financial Performance - The company achieved a gross margin of 85.2% in Q1 2025, an increase of 0.9 percentage points year-over-year, while the expense ratio decreased by 1.3 percentage points to 55.6% [8]. - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 1.09 RMB, 1.37 RMB, and 1.63 RMB, respectively [10]. Shareholder Information - The major shareholder is Jiangsu Hengrui Medicine Co., Ltd., holding 24.11% of the shares [1]. - Institutional investors hold 9.1% of the circulating A-shares, while general corporations hold 68.1% [2].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside of 15% to less than 35% [6][11]. Core Insights - The company reported a Q1 2025 revenue of 7.21 billion RMB, representing a year-over-year increase of 20.1%, and a net profit of 1.87 billion RMB, up 36.9% year-over-year [6]. - The significant profit growth in Q1 is attributed to a $75 million upfront payment from IDEAYA for a licensing agreement, with an estimated core revenue growth of approximately 11% after excluding this payment [8]. - The company has a robust pipeline with 26 innovative molecules entering clinical stages in 2024, covering various therapeutic areas, and is expected to showcase 15 innovative drugs at the upcoming ASCO conference [8]. - Future net profits are projected to be 6.98 billion RMB, 8.75 billion RMB, and 10.4 billion RMB for 2025, 2026, and 2027 respectively, with year-over-year growth rates of 10.2%, 25.3%, and 18.9% [10]. Summary by Sections Company Overview - The company operates in the pharmaceutical and biotechnology sector, with a market capitalization of 328.9 billion RMB and a share price of 51.56 RMB as of May 7, 2025 [1]. Financial Performance - The company achieved a gross margin of 85.2% in Q1 2025, an increase of 0.9 percentage points year-over-year, while the expense ratio decreased by 1.3 percentage points to 55.6% [8]. - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 1.09 RMB, 1.37 RMB, and 1.63 RMB respectively, with corresponding price-to-earnings (P/E) ratios of 47X, 38X, and 32X [10]. Shareholder Information - The major shareholder is Jiangsu Hengrui Medicine Group Co., Ltd., holding 24.11% of the shares, while institutional investors account for 9.1% of the circulating A-shares [2][1].

受理号：CXHS2500044、CXHS2500045 申报阶段：上市 申请人：江苏恒瑞医药股份有限公司 拟定适应症（或功能主治）：本品联合内分泌治疗用于激素受体（HR）阳性， 人表皮生长因子受体 2（HER2）阴性的早期或局部晚期乳腺癌的辅助治疗。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-074 江苏恒瑞医药股份有限公司 关于药品上市许可申请获受理的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）下发的《受理通知书》，公司自主研发的 CDK4/6 抑制剂羟乙磺酸达尔西利片药品上市许可申请获国家药监局受理。现将 相关情况公告如下： 一、药品的基本情况 药品名称：羟乙磺酸达尔西利片 剂型：片剂 二、药品的临床试验情况 SHR6390-Ⅲ-303 主要研究目的为评价达尔西利联合内分泌治疗在 HR 阳性、 HER2 阴性乳腺癌辅助治疗中的有效性，由复旦大学附属肿瘤医院及天津市肿瘤 医院牵头的约 ...

Core Viewpoint - Heng Rui Medicine has shown significant growth and innovation in 2024, achieving record-high revenues and profits, while also advancing its internationalization strategy through successful licensing agreements and a planned IPO in Hong Kong [1][5][14]. Financial Performance - In 2024, Heng Rui Medicine reported revenue of 27.985 billion yuan, a year-on-year increase of 22.63%, and a net profit of 6.337 billion yuan, up 47.28% [5]. - For Q1 2025, the company achieved revenue of 7.206 billion yuan, reflecting a 20.14% year-on-year growth, with a net profit of 1.874 billion yuan, increasing by 36.9% [5]. Innovation and R&D - Heng Rui Medicine has invested a total of 46 billion yuan in R&D as of Q1 2025, with innovative drug sales accounting for over 50% of total revenue [4][5]. - The company has 19 approved new molecular entity drugs and over 90 innovative products in clinical development, with 400 clinical trials ongoing [6]. Licensing and Partnerships - In 2024, Heng Rui Medicine secured two major licensing agreements totaling nearly $2 billion, marking a significant expansion in its business development (BD) strategy [8][9]. - The company has completed 14 licensing agreements, with potential total transaction amounts reaching approximately $14 billion in the last three years [10][11]. Internationalization Strategy - Heng Rui Medicine is pursuing a dual strategy of "innovation + internationalization," with plans to issue H-shares in Hong Kong to fund R&D and commercialization efforts [13][14]. - The company aims to optimize its international cooperation model and explore partnerships with multinational pharmaceutical companies and innovative startups [12][15]. Leadership Changes - The appointment of Feng Ji as the new president is seen as a move to accelerate Heng Rui Medicine's innovation and internationalization strategies [16]. Future Outlook - With a robust pipeline of innovative drugs and an expanding international presence, Heng Rui Medicine is positioned to play a more significant role in the global pharmaceutical market [17].

Core Insights - The latest net value of ICBC Frontier Medical Stock A (001717) is 2.8300 yuan, reflecting a decrease of 1.77% [1] - The fund has shown a one-month return of 5.28%, ranking 400 out of 471 in its category; a three-month return of 8.06%, ranking 71 out of 471; and a year-to-date return of 7.56%, ranking 113 out of 469 [1] Fund Holdings - The top ten holdings of ICBC Frontier Medical Stock A account for a total of 59.05%, with the largest positions being: - Heng Rui Medicine (10.11%) - Kelun Pharmaceutical (8.01%) - WuXi AppTec (7.72%) - BeiGene (6.85%) - Xinlitai (4.90%) - Zai Lab (4.77%) - Yuyue Medical (4.60%) - New Horizon Health (4.36%) - East China Pharmaceutical (4.20%) - Haizhi Pharmaceutical (3.53%) [1] Fund Overview - ICBC Frontier Medical Stock A was established on February 3, 2016, and as of March 31, 2025, it has a total scale of 9.081 billion yuan [1] - The fund manager is Zhao Bei, who has extensive experience in the healthcare sector [2]

Group 1 - The core point of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has seen a recent decline in net value and varying returns over different time frames [1] - As of May 7, 2025, the latest net value of the fund is 1.5753 yuan, reflecting a decrease of 1.28%. The fund's return over the past month is -2.61%, ranking 4118 out of 4649 in its category. Over the past three months, the return is 4.24%, ranking 1179 out of 4597, and since the beginning of the year, the return is 1.73%, ranking 2415 out of 4556 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Kanglong Chemical (6.24%) [1] Group 2 - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.613 billion yuan. The fund manager is Ms. Ge Lan [1] - Ms. Ge Lan has a background in biomedical engineering with a Ph.D. from Northwestern University in the United States. She has held various research and fund management positions before becoming the manager of the China Europe Medical Health Mixed Fund [2]